🏢 官网IRALMRDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 04:05:00(美东 10-08 16:05)·⟳ 抓取 04:08:50回填·⚡ 决策 10-09 04:09:31·18.8 天前
Alamar Biosciences宣布将于2026年11月3日盘后公布三季报，本次仅为财报日期预告
这是一条常规财报日程公告，未披露任何三季报数字、业绩指引、订单或产品商业化增量；真正的信息事件在2026年11月3日财报发布时才出现，当前没有可交易edge。
📄 原文ALMR↗ 原文
Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
FREMONT, Calif. , Oct. 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Prot…
不做 Alamar Biosciences, Inc.（ALMR.US）
常规财报日期预告，未包含三季报数据、指引、订单或其它新增基本面信息；当前无方向性edge，等待11月3日实际财报。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Alamar Biosciences只是提前公告三季报将于11月3日盘后发布，并未给出任何业绩数据或指引。该消息无新增基本面信息，方向性和预期差均不足，故不做。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 low ↗
关键理由
- 财报日期通知不改变公司收入、利润、现金余额或商业化前景，也不相对市场预期形成surprise。
主要风险
- 若市场此前完全未意识到财报窗口，11月3日前后波动率可能上升，但这不是本稿件本身提供的方向性交易理由。
先例如何影响了这次决策
对本次决策的影响:先例不改变结论，当前AVOID完全由缺乏增量事实决定。
方向:无需要用先例校准的方向；常规财报日期预告通常不是业绩surprise本身。
涨幅量级:没有对齐的业绩数据或指引事件，不能以历史财报波动幅度设定当前止盈止损。
形态:不对当前稿件套用见光死或财报行情模式；真正应研究的阶段是11月3日财报发布。
原文全文
展开原文 · 1,386 字
FREMONT, Calif.
,
Oct. 08, 2026
(GLOBE NEWSWIRE) --
Alamar Biosciences, Inc.
(Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report financial results for the third quarter 2026 after market close on
Tuesday, November 3, 2026
. Company management will webcast a corresponding conference call beginning at
1:30 p.m. Pacific Time
/
4:30 p.m. Eastern Time
.
Live audio of the webcast will be available on the “Investors” section of the company website at:
www.alamarbio.com
. The webcast will be archived and available for replay after the event.
About Alamar Biosciences, Inc.
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO™ HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at
alamarbio.com
.
Investor contact:
investors@alamarbio.com
Media contact:
media@alamarbio.com
,
Oct. 08, 2026
(GLOBE NEWSWIRE) --
Alamar Biosciences, Inc.
(Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report financial results for the third quarter 2026 after market close on
Tuesday, November 3, 2026
. Company management will webcast a corresponding conference call beginning at
1:30 p.m. Pacific Time
/
4:30 p.m. Eastern Time
.
Live audio of the webcast will be available on the “Investors” section of the company website at:
www.alamarbio.com
. The webcast will be archived and available for replay after the event.
About Alamar Biosciences, Inc.
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO™ HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at
alamarbio.com
.
Investor contact:
investors@alamarbio.com
Media contact:
media@alamarbio.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
41126ce317· 2026-10-09 04:09 · doubao / doubao-seed-evolving-latest-version · 策略包d5018cb8913f当前